Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
12,826 people get MRK articles and Market Currents by email alert.
Get email alerts on MRK »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
Merck's Liptruzet: A Cause For Shame?Derek Lowe • Thu, May 9 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Merck & Co.'s CEO Discusses Q1 2012 Results - Earnings Call TranscriptFri, Apr 27, 2012
-
Merck & Co. Inc. - Special CallThu, Nov 10, 2011
-
Merck & Co.'s CEO Discusses Q3 2011 Results - Earnings Call TranscriptFri, Oct 28, 2011
-
Merck & Co.'s CEO Discusses Q2 2011 Results - Earnings Call TranscriptFri, Jul 29, 2011
-
Merck & Co.'s CEO Discusses Q1 2011 Results - Earnings Call TranscriptFri, Apr 29, 2011
-
Merck CEO Discusses Q3 2010 Results - Earnings Call TranscriptFri, Oct 29, 2010
-
Merck & Co. Q2 2010 Earnings Call TranscriptFri, Jul 30, 2010
-
Merck & Co. Q1 2010 Earnings Call TranscriptTue, May 4, 2010
-
Merck & Co., Inc. Q4 2009 Earnings Call TranscriptTue, Feb 16, 2010
-
Merck & Co., Inc. Q3 2009 Earnings Call TranscriptThu, Oct 22, 2009
-
Merck & Co. Inc. Q2 2009 Earnings Call TranscriptTue, Jul 21, 2009
-
Merck F1Q09 Earnings Call TranscriptTue, Apr 21, 2009
-
at CNBC.com (Wed, 4:08PM)
-
at CNBC.com (Wed, 9:57AM)
-
at CNBC.com (Wed, 8:06AM)
-
at MarketWatch.com (Tue, 4:59PM)
-
at CNBC.com (Tue, 4:51PM)
-
at MarketWatch.com (Tue, 4:37PM)
-
at CNBC.com (Tue, 4:07PM)
-
at CNBC.com (Mon, 6:26PM)
-
at MarketWatch.com (Mon, 4:38PM)
-
at CNBC.com (May 17, 2013)
-
Business Wire (May 15, 2013)
-
at CNBC.com (May 6, 2013)
-
at CNBC.com (May 2, 2013)
-
at MarketWatch.com (May 1, 2013)
-
at CNBC.com (May 1, 2013)
-
at MarketWatch.com (May 1, 2013)
-
at CNBC.com (May 1, 2013)
-
at MarketWatch.com (May 1, 2013)
-
at Fox Business (May 1, 2013)
MRK vs. ETF Alternatives
Company Description
On November 3, 2009, Merck & Co., Inc. (“Old Merck”) and Schering-Plough Corporation (“Schering-Plough”) completed their previously-announced merger (the “Merger”). In the Merger, Schering-Plough acquired all of the shares of Old Merck, which became a wholly-owned subsidiary of Schering-Plough... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, January 8, 4:24 AM Merck (MRK) could be interested in acquiring Bausch & Lomb, with Merck CEO Kenneth Frazier saying "It's something that's worth thinking about." Any bid for Bausch & Lomb, whose owner, Warburg Pincus, hopes to get at least $10B in a sale, would be something of an about-turn for Frazier, as he previously said Merck isn't interested in large pharmaceuticals acquisitions. (previous) 4 Comments [Healthcare, M&A]
- Tuesday, December 11, 2012, 6:48 PM Goldman Sachs (GS) gets the nod by Warburg Pincus to explore a sale of Bausch & Lomb, the company's eye-care division. Warburg is said to be seeking at least $10B for the business. According to reports, Goldman has already contacted Sanofi (SNY), GlaxoSmithKline (GSK), and Merck (MRK) this month, and that Abbott Laboratories (ABT) will be among the other companies contacted. Comment! [Healthcare, M&A]
- Tuesday, June 26, 2012, 12:42 PM Five major drug companies are still in the hunt to acquire Amylin (AMLN) as the auction enters its final stage, Reuters reports, with final bids expected to start coming in at the end of the week. The runners and riders are Novartis (NVS), Sanofi (SNY), Bristol Myers (BMY), AstraZenica (AZN) and Merck (MRK). (See also) Comment! [M&A, Healthcare]
- Friday, May 25, 2012, 4:28 PM Shares of Amylin Pharmaceuticals (AMLN +8.4%) finished markedly higher on reports that the company, which is on the sales block, was already receiving bids from Sanofi (SAN) and Merck (MRK) in excess of $25 per share. 1 Comment [Healthcare, On the Move, M&A]
- Tuesday, May 15, 2012, 11:52 AM Amylin (AMLN) +6% to $27.19 on reports that it's attracted multiple suitors. Leerink Swann analysts reckon Sanofi (SNY) and Merck (MRK) will emerge as the strongest bidders, and predict a sale price in the mid-$30 a share, although it could go higher if there's a bidding war for the biotech firm. 1 Comment [On the Move, M&A, Healthcare]
- Wednesday, March 28, 2012, 3:09 PM Amylin (AMLN +48.6%) investors cheer the rumor it rejected a $3.5B offer from Bristol-Myers Squibb, and analysts expect higher bids. Deutsche Bank says AMLN could be worth up to $31/share given an "acquirer with diabetes sales force can cut SG&A by 80% and R&D by 40%." Piper Jaffray names BMY, MRK and TKPYY.PK as potential sutiors; Leerink Swann suggests AZN. Comment! [Healthcare, M&A, On the Move]
- Monday, October 17, 2011, 6:13 PM GlaxoSmithKline (GSK) may bid $25/share for Human Genome Sciences (HGSI), the Daily Mail speculates, citing their partnership in developing the FDA-approved lupus drug Benlysta. With Merck (MRK) and Biogen (BIIB) also sniffing around the company, GSK "could decide now would be an opportune time to make a move on HGS." HGSI +4.9% AH. 2 Comments [Healthcare, M&A]
-
- View all 1 replies
-
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 1 replies
-
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
- View all 1 replies
-
-
- View all 4 replies
-
-
-
- View all 1 replies
-
-
- View all 2 replies
-
-
Chines33: Almost reshorted it on the close but will wait to see what happens at open.
-
- View all 15 replies
-
SKS1586: andyk80: Mr Market is listening to you & following your thought of bounce, with uptick in all the Futures @ this moment.
-
-
- View all 2 replies
-
-
SKS1586: joe kelly - I reduce or remove my positions for creation of CASH. Therefore I leave trades with much less profit than most Investors/Traders
-
Ryan Mallory
16 Defensive Stock Plays to Weather Market Uncertainty http://bit.ly/RVR8Ko AAPL ABT AMZN AZN MRK NVS PEP to name a few of them - View all 1 replies
-
driftking27: How do you see the strong CHf affecting there growth. I think that could be one hurdle that could hurt there sales. Plus NVS drops more...
-
- View all 6 replies
-
J. Sheehan: In @ $35.05, and plan on holding unless something crazy happens. Might take some profits before Q412 ER.
-
J. Sheehan: I know prescriptions for Singulair were down 90% in the U.S. just a month after U.S. patent expiration in August.
-
David Crosetti
It's a beautiful day in the neighborhood! Great rally! Rebalancing the portfolio today! Hot dog! MRK up 4%?? Wow. - View all 6 replies
-
-
-
- View all 6 replies
-
-
-
- View all 13 replies
-
John Rayhall: IDIX has a huge buyout premium in already was 7 before the INHX buyout. Any bad news and it'll get crushed. -
-
Dividend Sheet
Best Healthcare Stock Picks For 2012: http://bit.ly/w32xHl + $MRK $NVS $STJ $TEVA $TMO $CELG $GILD - View all 2 replies
-
-
-
- View all 2 replies
-
-
-
- View all 9 replies
-
-
FortSumter: Out today at $37.50. Just based on technicals there will soon be another entry point.
-
- View all 2 replies
-
-